Is CAR T-cell therapy right for multiple myeloma?

Learn about candidates, risks, outcomes, and quality of life after treatment.

🗓 May 6
🕐 1:15p ET | 12:15p CT | 11:15a MT | 10:15a PT

Register: bmtinfonet.org/registration...

#CARTCellTherapy #MultipleMyeloma #BMTInfoNet #CancerSurvivorship

Is CAR T-cell therapy right for you?

Learn about candidates, risks, outcomes, and quality of life after treatment.

🗓 May 5
🕞 3:45 p.m. ET | 2:45 p.m. CT | 1:45 p.m. MT | 12:45 p.m. PT

Register: bmtinfonet.org/registration...

#CARTCellTherapy #Lymphoma #BMTInfoNet #CancerSurvivorship

Nanotechnology-enhanced Chimeric Antigen Receptor-T Cell Therapy for Ovarian Cancer Chimeric antigen receptor (CAR)-T cell therapy faces significant challenges in treating solid tumors, including immune evasion, suppressive tumor microenvironments, and on-target/off-tumor toxicity, which limit its clinical efficacy. Although it has revolutionized treatment for hematological malignancies, these obstacles hinder its broader application in solid tumors. Nanotechnology offers innovative strategies to address these limitations through enhanced delivery, localization, and control. This review summarizes recent advances in nanotechnology-assisted CAR-T cell therapies for gynecologic cancers, with a particular focus on messenger RNA (mRNA)-based delivery systems, lipid nanoparticles, hydrogels, and external activation techniques such as photothermal and acoustogenetic modulation. The integration of nanotechnology, especially mRNA-based delivery systems, holds transformative potential for overcoming these barriers. mRNA enables transient, non-integrating expression of CARs, meaning the genetic modifications are temporary. This improves safety and allows flexible control over treatment intensity, while rational sequence optimization (e.g., codon usage, guanine-cytosine content, secondary structure) enhances mRNA stability and protein translation efficiency. Lipid nanoparticles, the leading delivery platform, can be engineered for cell-type specificity and tissue targeting through modulation of their components and surface functionalization. Recent innovations, including siloxane-modified lipid nanoparticles, injectable hydrogels, and photothermal or acoustogenetic activation strategies, enable precise spatiotemporal control of CAR-T cell function in vivo. In ovarian cancer, preclinical studies targeting nfP2X7 and employing multifunctional nanoparticles have demonstrated synergistic efficacy and tumor-specific delivery. This review highlights how nanotechnology platforms can be integrated with CAR-T cell therapies to enhance safety, precision, and therapeutic outcomes in ovarian cancer.

🎗️ Nanotechnology could help CAR-T therapy break through in ovarian cancer by improving trafficking, persistence, and tumor-site performance. @icr.ac.uk
#CARTCellTherapy
🔗 www.xiahepublishing.com/2996-3427/On...

Zelig Eshhar: The Pioneer Who Re-Engineered the T-Cells and Brought CAR-T into the World

dl.begellhouse.com/journals/439...

#CARTCellTherapy #CancerImmunotherapy #TcellEngineering #CRO

Recovery after CAR T-cell therapy continues beyond treatment.

Learn about long-term side effects, risk factors, and how to monitor and manage your health moving forward.

🗓 May 4
🕝 2:30 p.m. ET

Register: bmtinfonet.org/registration...

#CARTCellTherapy #BMTInfoNet #CancerSurvivorship

Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancer - Nature Biomedical Engineering A pan-haematologic cancer approach, involving analysis of data from 256 patients across 5 cancer types and 13 clinical trials, revealed predictive biomarkers for understanding the response or non-resp...

Leveraging #ComputationalBiology at scale to individualize #Immunotherapy: www.nature.com/articles/s41... @JoeFraietta @carlhjune #CARTcelltherapy #CellTherapy #CARTCell #TranslationalScience

Cancer treatment: Optimization of CAR T-cell therapy – BioNews Central Researchers improve the efficacy of CAR T-cell therapy in solid tumors by modifying T cells to make them resistant to local inhibition within the tumor microenvironment. ...

Researchers improve the efficacy of #CARTCellTherapy in #SolidTumors by modifying #TCells to make them resistant to local inhibition within the #TumorMicroenvironment.
#CancerTreatment

How do teams assess readiness for transplant or CAR T in older adults?

Episode 6 of Thrive! explores frailty and resilience with guidance from Dr. Amelia Langston.

Apple: podcasts.apple.com/us/podcast/t...
YouTube: youtu.be/sSlvjW1fW1Q

#StemCellTransplant #CARTCellTherapy

🚪 Doors are open 🎬 The 8th European CAR T-cell Meeting starts with the Opening Session at 12:30 CET.

🏛️ See you at the event venue 📍 Palma Convention Centre or 💻 online in the virtual meeting platform. 🙂

We hope you enjoy #CART26! 👏

#CARTcelltherapy #cellulartherapy

Scientific poster explaning the findings - CONCLUSION For patients and caregivers, travel time and cost , difficulties with care coordination, securing a 24/7 caregiver, and the perceived risk of side effects are the most significant barriers to CAR T. • Having to travel long distances to academic cancer centers away from patients’ primary care sites for CAR T cell therapy compounded the psychosocial and financial burden associated with receiving CAR T for patients and caregivers. • The time, financial, and social toxicity associated with CAR T cell therapy impacts patients, caregivers, families, and communities. • CAR T should be made available at more care sites and supportive resources should be made more widely available to reduce the financial, logistic, and psychosocial burden of CAR T and improve access to this innovative therapy

Why do 80% of eligible patients miss out on life-saving #CARTCellTherapy?

www.CancerSupportCommunty.org's research reveals real barriers—financial toxicity, travel burden, caregiver strain—that keep patients from accessing CAR T.
#Tandem26, ⏰ 6:30-8p, 📅 Th, 2/5

#CART #HealthEquity
bit.ly/3LRWDwh

📣 Late-breaking abstract submission for #CART26 is now open. 📰 Take advantage of this second chance to highlight the latest developments in your research. 🔬
Learn more: 🔗 www.ebmt.org/events/ebmt-eha-8th-euro...

#abstractsubmission #CellTherapy #CARTcelltherapy

Spain CAR T Cell Therapy Market Size, Share, Forecast 2035 Spain Car T Cell Therapy Market share register 221.71 USD Million in 2024, projected to grow 15.48 % CAGR to reach USD Million 1079.98 during the forecast period 2025 - 2035.

🧬 Spain’s CAR-T cell therapy market is advancing personalized cancer treatment. www.marketresearchfuture.com/reports/spai... #CARTCellTherapy #Oncology 🇪🇸

CAR-T Cell Therapy: Revolutionizing Cancer Treatment and its Implications for Future Therapeutic Strategies: A Review - Premier Science Palak Parmar, Sangeeta Dwivedi , Vikas K. Jain, Hariom Carpenter and Gajanand DarwhekarDepartment of Pharmacology, Acropolis Institute of Pharmaceutical

doi.org/10.70389/PJS...

#carTcelltherapy #cancertreatment #cancer #oncology

CAR T-cell therapy promotes rejuvenation of intestinal epithelium – BioNews Central Biologists have developed a new method using CAR T-cell therapy to stimulate growth and repair of the intestinal epithelium, potentially advancing treatments for age-related gut disorders. ...

Biologists have developed a new method using #CARTCellTherapy to stimulate growth and #repair of the #IntestinalEpithelium, potentially advancing treatments for #AgeRelated #GutDisorders.
#Aging #Senescence #LeakyGut #LeakyGutRepair #Immunotherapy

A routine blood test could help predict who benefits most from CAR T-cell therapy – BioNews Central Measuring a patient’s absolute lymphocyte count can help predict their response to CAR T-cell therapy for non-Hodgkin lymphoma, providing a practical tool to guide treatment decisions. ...

Measuring a patient’s absolute #LymphocyteCount can help predict their response to #CARTcelltherapy for #NonHodgkinLymphoma, providing a practical tool to guide #TreatmentDecisions.
#TherapyResponse #ClinicalOutcomes

Fred Hutch at #ASH25: Catch Dr. Emily Liang present "High-dose anakinra to treat refractory immune effector cell-associated neurotoxicity syndrome in #CARTcelltherapy recipients" 👉 https://bit.ly/4rCgeQL

For many blood cancer patients, CAR T-cell therapy is game-changing CAR T-cell therapy, which transforms patients’ own immune cells into cancer-fighting warriors, has been extremely effective against lymphoma, multiple myeloma and certain leukemias. Mazyar Shadman, MD...

Ahead of #ASH25, we sat down with Dr. Mazyar Shadman, medical director of cellular #immunotherapy at Fred Hutch, to discuss the barriers to accessing #CARTcelltherapy and what patients and providers should know about this treatment: https://bit.ly/3KqbNIk

A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myeloma Rade et al. present a longitudinal single-cell atlas of BCMA CAR-T therapy in multiple myeloma, revealing that cilta-cel drives potent CD4⁺ cytotoxic responses and superior outcomes. Their findings id...

A longitudinal study led by Dr. Maximilian Merz sheds new light on why cilta-cel yielded better response rates compared to ide-cel for those with relapsed/refractory #multiplemyeloma. @mskcancercenter.bsky.social #mmsm @szusmani.bsky.social #CARTcelltherapy

A tumor-on-a-chip for in vitro study of CAR-T cell immunotherapy in solid tumors - Nature Biotechnology The interactions of CAR-T cells and solid tumors are modeled on a chip.

Advancing chimeric antigen receptor #CARTcellTherapy for #SolidMalignancies through tumor-on-a-chip technology www.nature.com/articles/s41... #OrganTumorOnAChip #Cancer #CellTherapy #CARTCell #ImmunoTherapy #Oncology #TranslationalScience

An overview of #CARTcelltherapy, examining applications in #HematologicMalignancies and #SolidTumors, while highlighting ongoing trials and future directions for effective CAR-T therapies in #AML. @idibaps.bsky.social #medsky

#OpenAccess in #STTT: doi.org/10.1038/s413...

#CellandGeneTherapy #CGT #Uniphar #personalisedmedicine #Celltherapy #CARTcelltherapy #Genetherapy #CGTlandscape #CGTpipeline #genetherapytrials #Expandedaccess #NamedPatientSupply #FreeofChargeaccess #FOCaccess #MAPs #EAPs #realworldevidencegeneration #marketreadiness
zurl.co/2pdyj

As we still celebrate the Laureates 2025, let’s take a closer look at the Laureates’ groundbreaking research on CAR-T cell therapy – and what makes it so transformative for the future of medicine! #CancerResearch #MedicalInnovation #cartcelltherapy #cancer #cancercure

As we still celebrate the Laureates 2025, let’s take a closer look at the Laureates’ groundbreaking research on CAR-T cell therapy – and what makes it so transformative for the future of medicine! #CancerResearch #MedicalInnovation #cartcelltherapy #cancer #cancercure

As we still celebrate the Laureates 2025, let’s take a closer look at the Laureates’ groundbreaking research on CAR-T cell therapy – and what makes it so transformative for the future of medicine! #CancerResearch #MedicalInnovation #cartcelltherapy #cancer #cancercure

As we still celebrate the Laureates 2025, let’s take a closer look at the Laureates’ groundbreaking research on CAR-T cell therapy – and what makes it so transformative for the future of medicine! #CancerResearch #MedicalInnovation #cartcelltherapy #cancer #cancercure

As we still celebrate the Laureates 2025, let’s take a closer look at the Laureates’ groundbreaking research on CAR-T cell therapy – and what makes it so transformative for the future of medicine!

#CancerResearch #MedicalInnovation #cartcelltherapy #cancer #cancercure

Turning All Cancers Into Curable Diseases - Dr. Karen Knudsen MBA PhD - CEO, Parker Institute for Cancer Immunotherapy, joins me on Progress, Potential, And Possibilities #ProstateCancer #CARTCellTherapy #CheckpointInhibitors #TumorAntigens #TumorMicroenvironment www.youtube.com/watch?v=cyrO...

Kraft Family Blood Donor Center

On Apheresis Awareness Day, the Kraft Family Blood Donor Center honors donors, apheresis practitioners & patients for whom T-cells are removed, modified in the lab and infused back so they are stronger and ready to attack cancer head-on. #CARTCellTherapy #TCellCollection @danafarber.bsky.social

Jan Janisch-Hanzlik had been having strange symptoms for several years. But it was a sensation that started in her toes and crept up her right side that really concerned her.

buff.ly/gBfzHzM

#MED #NebraskaMedicine #MultipleSclerosis #CARTCellTherapy

REVIEW: Aging and immunity: the age-old tango
by Fernández Maestre et al. @corina-amor.bsky.social‬ @cshlaboratory.bsky.social‬
➡️ https://tinyurl.com/gd352644

#aging #senescence #cancer #immuneregulation #antiaging #immunotherapy #CancerImmunotherapy #Inflammaging #CARTCellTherapy #CART

This review outlines #CARTcelltherapy in hematologic & solid #tumors, highlights challenges in #AML therapy, explores ongoing #ClinicalTrials, & discusses strategies to optimize AML therapy. #medsky @idibaps.bsky.social

Latest in #STTT #OpenAccess: www.nature.com/articles/s41...

CAR T-Cell Therapy: A New Frontier in Cancer Immunotherapy - OncoDaily Explore how CAR T-cell therapy works, its approved uses, challenges in solid tumors, and future innovations in precision immunotherapy.

CAR T-Cell Therapy: A New Frontier in Cancer Immunotherapy

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #CARTCellTherapy #CART #Immunotherapy #IO

In vivo screening reveals cell-intrinsic mediators of solid tumor resistance to CAR T cell-therapy
Chen, E., Doherty, S. et al.
Paper
Details
#CARTCellTherapy #SolidTumorResistance #InVivoScreening

CARTITUDE-1: Single #CARTCellTherapy infusion shows potential for cure in relapsed/refractory #MultipleMyeloma
📊 5-year PFS in 33% of patients; MRD & PET-negative in subset
📰 July cover story of The ASCO Post
👨‍⚕️ Peter M. Voorhees, MD
🔗 ascopost.com/issues/july-...